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Introduction
Economic studies in health care play a less important 
role in decision-making in health care in Italy than in 
some other European countries. Nevertheless, since 
1997, in order for a new drug to obtain its price and 
reimbursement, the negotiation between authorities 
and the pharmaceutical industry must include, among 
other, an economic evaluation in addition to an esti-
mate of the impact on the domestic market in terms of 
public pharmaceutical expenditure and the effects on 
the national economy (employment and invest-
ments).1 Physicians are aware of the importance of 
such data for policy,2 and a considerable number of 
studies on the cost of multiple sclerosis (MS) have 
been published in the past decades.3–8
The availability of disease-modifying treatments 
(DMTs) has led to changes in patient management and 
more focus on earlier and better diagnosis, including 
new diagnostic criteria.9–11 One of the consequences in 
this regard is that the recorded prevalence of the disease 
is quite different from that estimated two or three dec-
ades ago.12,13 A recent review of prevalence estimates of 
MS in Italy over the last 40 years reported a large varia-
tion by region, with 130 patients per 100,000 population 
in Lazio, 188/100,000 in Tuscany and 176/100,000 and 
299/100,000 in Sicily and Sardinia, respectively.14 With 
diagnosis possible already after a clinically isolated 
event,10 one must also expect a different distribution of 
the type of MS and the severity of the disease than 10 
years ago: a larger proportion of patients with relapsing-
remitting disease and thus of patients in the early stages 
of the disease with less disability.
Therefore, it is important to update the information on 
the burden of MS, and this study is part of a European-
wide effort in 16 countries, endorsed by the European 
Platform of MS Societies (EMSP) and carried out 
with the support of national MS societies.15 It uses a 
similar methodology as the last European survey in 
2005 that also included Italy.4,16
Materials and methods
The detailed methodology for this European survey is 
published separately.16 We therefore only provide a 
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short summary of the general methods and issues spe-
cific to Italy.
Data
This study aimed to estimate the costs of all health 
care and other resource utilisation related to MS: hos-
pitalisation, rehabilitation, consultations, diagnostic 
procedures and tests, medication, community care, 
family support and production losses (sick leave, 
early retirement and invalidity). In addition, informa-
tion on major symptoms such as fatigue and cogni-
tive difficulties, health-related quality of life 
(HRQoL) as well as self-assessed disability using 
descriptions based on the Expanded Disability Status 
Scale (EDSS) was collected.
Data were collected with a standard questionnaire, 
at a single point in time, for a retrospective period 
of time. The latter was varied depending on the 
question in order to minimise recall bias: 1 month 
for use of drugs, community services and family 
help; 3 months for hospitalisation, consultations, 
tests, sick leave and relapses; and 12 months for 
major investments. Resource utilisation is reported 
for these time periods, while cost calculations are 
annualised.
Disease information (type of MS, disability (EDSS), 
HRQoL, utility (EuroQol five-dimensions (EQ-
5D)17), symptoms (fatigue and cognitive difficul-
ties) and the effect of MS on work related to the 
current day or week. For comparability across coun-
tries,15 utilities are estimated with the original value 
set developed in the United Kingdom.18 This tariff 
is generally used in studies in Italy. However, 
Scalone et al.19 established an Italian tariff applying 
the same methodology as used for the UK tariff with 
individuals from the general population, and there-
fore, we also present utilities established with this 
local tariff.
The handling of missing data for the cost calculation 
is explained in more detail in the paper describing the 
methods.16 For resource use, we present actual 
answers without any imputation for missing answers. 
Also, no imputations are made for missing informa-
tion on disease status, symptoms and HRQoL.
Costs
Costs are calculated in the societal perspective, 
including all costs regardless of who ultimately is 
responsible for them. Patient co-payments and 
patients’ out-of-pocket expenses are thus included.
The cost of a relapse is calculated as the difference 
in quarterly costs between patients with or without a 
relapse and an EDSS score of 0–6; patients who 
were unsure were excluded from the estimation. 
Invalidity, early retirement and DMT costs are not 
considered in the calculation as these are unlikely to 
be affected within 3 months. Unit costs for the indi-
vidual resources were taken from public sources and 
described in the paper on the study methodology,16 
and results are reported in EUR 2015.
Patients
The objective was to include a sample where all levels 
of disease severity (defined by EDSS) were repre-
sented in sufficient numbers to permit analysis, rather 
than a prevalence sample. This allows highlighting 
how costs and HRQoL change as the disease pro-
gresses and provides the necessary data for cost-
effectiveness analysis of treatments that are expected 
to change the course of the disease. Mean results may 
thus not be representative and should neither be 
extrapolated directly to national costs nor be com-
pared directly to the results in earlier studies. We 
therefore report results by disease severity groups 
only (mild MS, EDSS = 0–3; moderate MS, EDSS = 
4–6.5; and severe MS, EDSS = 7–9).
Data collection
In anonymous surveys, it is difficult to include a fully 
representative patient population, and changes in the 
management of MS, in particular earlier diagnosis, 
have increased this challenge. In addition, participa-
tion will depend heavily on the methods used for the 
survey: collecting data in MS centres tends to overes-
timate the number of patients with early but severe 
disease and on treatment with DMTs;20 collecting data 
from members of patient organisations may lead to 
the opposite. Internet surveys will bias towards 
younger patients with better education, while postal 
mailing may bias towards older patients.
The Italian participants in the study presented here 
were all people in contact with the Italian Multiple 
Sclerosis Association (AISM). The data were col-
lected during spring and summer 2015. AISM invited 
4000 individuals to participate in the survey with a 
web mailing list regularly used to distribute informa-
tion. This sample of online users from the AISM is 
typically rather young (mean age = 43.5 years). To 
also include older patients with more advanced disa-
bility, 200 patients were contacted personally by staff 
from the regional offices of AISM and their answers 
collected on paper.
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Results
A total of 1010 evaluable responses were received. 
All patients invited by mail answered electronically 
(80%), while the 200 patients contacted directly com-
pleted paper questionnaires. The geographical distri-
bution of respondents represented well the proportion 
of inhabitants of the different regions, with, however, 
a slight overrepresentation in Sardinia and Tuscany 
and an underrepresentation in Campania and Sicily.21 
Table 1 provides details on demographics, employ-
ment and disease.
Demographics and employment
The age of respondents in Italy ranged from 19 to 84 
years (mean = 45 years, median = 44 years and 
standard deviation (SD) = 12.0 years). Women rep-
resented 70% of the sample; 87% lived with their 
family and only three patients lived in a nursing 
home at the time of the survey. Education levels in 
our sample were considerably higher than in the 
general population of that age, as would be expected 
in this mostly online survey: 17% of patients had 
basic education, 52% had a secondary or a profes-
sional degree and 30% a university degree. This 
compares to 36% of the population with primary 
education, 47% with upper secondary education and 
19% with tertiary education in 2015.22
The majority of patients in the sample were below 
retirement age (defined as effective retirement age, 
60.5 years for women and 61.1 years for men23): 950 
patients (94%). Of these, 533 patients (56%) were 
employed or self-employed. One patient above retire-
ment age also worked, bringing this group to 534 
patients (or 53% of the full sample), with a mean age 
of 46.6 years. This compares to an employment rate 
of 60.5% in the general population aged 20–64 years 
in 2015.24 However, 96% of employed patients 
worked part-time, on average 23 hours/week; 84% of 
these did so due to MS, confirming indeed the effect 
of MS not only on employment but also on working 
time. In addition, 6% of employed patients were on 
long-term absence, while short-term sick leave during 
the past 3 months was reported by 215 patients (23%), 
with a mean duration of 12 days.
Employment decreased rapidly with advancing dis-
ease, as shown in Figure 1. Of non-employed patients 
below retirement age, 20% indicated MS as the rea-
son for leaving the workforce.
Most employed patients felt that MS affected their 
productivity at work (77%), and only 12% indicated 
that they had no problems related to work, while 
10.5% had not answered this question. The severity 
of the effect covered the entire visual analogue scale 
(VAS) range from 0 to 10, with a mean of 3.6 (SD = 
2.6; Figure 2). Fatigue was considered the most both-
ersome symptom (78%), followed by cognitive dif-
ficulties (30%), low mood (27%), mobility (23%) 
and pain (17%).
Disease characteristics
Data on disease characteristics are summarised in 
Table 1. As a consequence of mean age of the Italian 
sample, the mean EDSS was low (3.7, SD = 2.6) and 
the group with early or mild disease was very large. 
The mild group represented 53% of the sample, the 
moderate group 31% and the severe group 16%. 
However, the number of patients at each EDSS score 
exceeded 50 with the exception of EDSS 9 with 19 
patients only.
Similarly, a majority of patients (67%) had relaps-
ing-remitting multiple sclerosis (RRMS), while 20% 
had secondary progressive multiple sclerosis 
(SPMS) and 12% had primary progressive multiple 
sclerosis (PPMS), with 1% missing. Considering 
this group with recent diagnoses, the proportion of 
PPMS is probably higher than seen in recent stud-
ies25 and suggests, as we found in previous studies, 
that patients were insecure in their answers regard-
ing the type of disease. We therefore did not include 
the disease course in our analyses and focussed on 
EDSS levels instead. Nevertheless, the high propor-
tion of RRMS and young age may partly explain that 
DMTs were used by 69 of the sample, with usage 
declining with higher EDSS levels, as expected 
(Table 1). Among users, 31% were on their first 
DMT treatment; first-generation DMTs were used 
by 64% of users (Table 2).
Relapses in the preceding 3 months were reported by 
142 patients (14%), of which half occurred in the 
past month (Table 1). However, 189 patients (19%) 
were unsure whether they had a relapse or not, and 
we assumed that the answer was no. Thus, the mean 
relapse rate over a 3-month period was estimated at 
0.2 (SD = 0.5). Corticosteroids were administered to 
62% of the patients with relapses, most often as 
infusion.
Symptoms and HRQoL
Fatigue and cognitive difficulties were an issue for the 
majority of patients, and both were related to disease 
severity (Figure 2). Fatigue was present in 96% of the 
patients (1% missing). The mean VAS score was 5.9 
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(SD = 2.6) for the whole sample, 4.9 for patients with 
mild disease, 7.0 for patients in the moderate group 
and 7.3 for patients in the severe group. Cognitive dif-
ficulties were present in 65% of all patients. The mean 
VAS score in this group was 4.6 (SD = 2.1) overall, 
4.1 in the mild, 5.1 in the moderate and 5.5 in the 
severe group. For the full study sample (assigning 0 to 
the group with no problems), the mean score was 3.7 
(SD = 2.8), with scores of 2.6 in the mild and 3.5 in 
the moderate and severe groups.
All five domains of HRQoL included in the EQ-5D18 
represented problems for a large proportion of 
patients: pain/discomfort for 73%, usual activities for 
67%, mobility for 60%, anxiety/depression for 59% 
and self-care for 32%. Both the severity and the 
affected domains changed with advancing disease. 
Self-care was unaffected in patients with mild disease 
but declined very rapidly with advancing disease, 
with <10% without difficulties in the severe disease 
group; mobility, pain and usual activities presented 
problems for almost all patients already with moder-
ate disease; most noticeably, however, anxiety/depres-
sion was present in about 60% of the patients at all 
levels of disease severity (Figure 3).
Utility
Utility scores declined with increasing disability 
(EDSS; Figure 4). Mean utility in this specific sample 
of patients was 0.575 and 0.744 using the UK and 
Italian value sets, respectively. The scores with the 
UK value set are very similar to those found in a 
recent study with a similar patient population.8
Table 1. Demographic and disease information.
Sample Mild MS, 
EDSS = 0–3
Moderate MS, 
EDSS = 4–6.5
Severe MS, 
EDSS = 7–9
N 1010 532 (52.7%) 315 (31.2%) 163 (16.1%)
Proportion women 70.4% – – –
Proportion living alone 12.4% 63 (11.8%) 38 (12.1%) 24 (14.7%)
Mean age (SD, years) 45.0 (11.9) 39 (9.5) 49 (10.5) 56 (10.8)
Education
 Primary school 17.0% – – –
 High school or professional diploma 52.4% – – –
 University education 29.9% – – –
Employment
 Patients of working age 950 (94.1%a) 530 (99.6%) 292 (92.7%) 128 (78.5%)
 Total currently employed or self-employed 534 (52.9%a) 365 (68.6%) 143 (45.4%) 26 (16.0%)
 Working age, employed or self-employed 533 (56.1%b) 365 (68.9%) 142 (48.6%) 26 (20.3%)
 Working full timec 22 (4.1%d) 11 (3.0%) 10 (7.0%) 1 (3.8%)
 On long-term leave (>3 < 12 months) 32 (6.0%d) – – –
 Sick leave (past 3 months) 215 (40.3%d) – – –
 Not working due to MS 190 (20.0%b) – – –
 Invalidity pension 115 (12.1%b) 9 (1.7%) 56 (19.2%) 50 (39.1%)
 Early retired 38 (4.0%b) 3 (0.6%) 16 (5.5%) 19 (14.8%)
Disease information
 Mean age at diagnosis (SD) 34.2 (10.4) 32 (8.9) 37 (11.0) 37 (11.7)
 Mean age at first symptoms (SD) 29.1 (9.2) 29 (8.6) 30 (10.1) 30 (9.6)
 Mean EDSS (SD) 3.7 (2.6) 1.5 (1.0) 5.3 (0.9) 7.7 (0.7)
 Proportion with RRMS 674 (66.7%) – – –
 Proportion with relapses 142 (14.1%) 63 (11.8%) 54 (17.1%) 25 (15.3%)
 Proportion using DMTs 694 (68.7%) 82.9% 65.1% 29.4%
MS: multiple sclerosis; SD: standard deviation; EDSS: Expanded Disability Status Scale; DMT: disease-modifying treatment; 
RRMS: relapsing-remitting multiple sclerosis.
a Of total sample (N = 1010).
b Of patients of working age (n = 950).
c Full-time work defined as 36 hours/week.
d Of patients working (n = 534).
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Figure 1. Employment by disease severity.
EDSS: Expanded Disability Status Scale.
Proportion of patients below retirement age who are employed or self-employed. In total, 950 patients (94%) were below retirement age, 
and of these, 56% were employed or self-employed. Among these, 32 patients were on long-term absence.
Figure 2. Fatigue, cognitive difficulties and effect of MS on productivity at work.
EDSS: Expanded Disability Status Scale.
Mean score on the visual analogue scales (0 = no problem; 10 = severe problems) for fatigue, cognitive difficulties and impact of MS on 
work (only for patients working). Proportions calculated on the full sample who answered the question, assigning 0 to patients with no 
problems.
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Resource utilisation
Resource utilisation is presented in Table 3. Inpatient 
admissions were rare, occurring in patients with a 
severe relapse or severe disease who spent the major 
part of the preceding 3 months in hospital: 46 patients 
(5%) were admitted as inpatients, most often to a 
neurology ward, 6 times on average and for a mean of 
10.9 days (SD = 16.7 days). Day admissions were 
reported for 187 patients (19%) and were most likely 
linked to treatment administration, on average once a 
month. Inpatient or day admissions to rehabilitation 
centres occurred for 89 patients (9%).
Table 2. Type of DMTs used (N = 694).
First-generation treatments Percentage of 
total users
Second-generation treatments Percentage of 
total users
Interferon-beta 1b (Betaferon®/Extavia®) 6.2 Natalizumab (Tysabri®) 10.4
Interferon-beta 1a (Avonex®) 14.3 Fingolimod (Gylenia®) 19.5
Interferon-beta 1a (Rebif®) 22.8 Teriflunomide (Aubagio®) 3.7
Glatiramer acetate (Copaxone®) 15.0 Dimethyl fumarate (Tecfidera®) 3.3
Peginterferon-beta 1a (Plegridy®) 0.1  
Mitoxantron (Novantrone®) 0.9  
Azathioprine (Immurel®) 5.0  
DMT: disease-modifying treatment.
Figure 3. Problems in different domains of QoL (EQ-5D; N=1010).
Proportions of patients at different levels of disease severity experiencing difficulties in the five domains of the EQ-5D (EuroQol-5 
dimensions). All domains represent problems for patients already in mild disease, except the ability for self-care that declines, however, 
very rapidly with worsening disease. Anxiety/depression is present with similar severity at all stages of the disease.
EQ-5D: EuroQol-5 dimensions; EDSS: Expanded Disability Status Scale.
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A majority of patients (820 patients, 81%) had a consul-
tation during the past 3 months, most often with neu-
rologists (71%), physiotherapists (21%) and general 
practitioners (19%). Investigations and tests were done 
for 63% of patients, with 360 patients (36%) undergo-
ing magnetic resonance imaging (MRI) of the brain and 
258 patients (26%) of the spine. Medications for MS 
and MS-related symptoms were used by 91% of the 
patients during the past month. Drugs other than 
DMTs (including corticosteroids) were used by 53% of 
the patients, predominantly treatments for walking, 
spasticity and pain (22%) and depression (11%). Non-
prescription drugs were used by 64% of the patients.
Investments in equipment and devices to aid patients’ 
mobility were made during the past 12 months for or 
by 23% of the patients, most often for walking/mobil-
ity aids and modification to the house or the car.
Community and social services were used by 17% of 
the patients, most frequently home help. Help from 
family was used by 44% of the patients, on average 
16.8 (SD = 11.8) days per month and 6.3 (SD = 7.3) 
hours per day. Both community services and informal 
care were related to disease severity (Figure 5).
Costs
Total mean annual costs per patient for patients with 
mild, moderate and severe disease and by EDSS score 
are presented in Figure 6 and Table 4.
The average cost of a relapse for patients with an 
EDSS between 0 and 6 was estimated at €2620. 
All types of costs increased during a relapse, with 
hospital care representing 43% of the additional 
cost, informal care 28% and sick absence 11% 
(Figure 7).
Discussion
This study provides an update to the current under-
standing of the burden of MS on patients, the health 
care system and society in general in Italy based on 
a cross-sectional survey conducted in 2015.
The Italian sample was young, as a result of mainly 
enrolling patients using a web mailing list, and 
although it included patients at all levels of disabil-
ity, there was an overrepresentation of patients with 
early disease. Consequently, we did not extrapolate 
the mean cost in this sample to a national cost esti-
mate, as it would likely result in an underestima-
tion. The enrolment method may also partially 
explain the better educational attainment in our 
sample compared to the general population. Age 
and education may, in turn, explain that the absolute 
employment rate was not substantially lower than in 
the general population.
Overall, our results are in agreement with the litera-
ture, showing that the costs of MS increase with ris-
ing EDSS level, while utilities (QoL) decrease.26
Figure 4. Utility by EDSS (N=1010).
Utility by EDSS level estimated with the EQ-5D using both the UK and Italian value sets.17,18 Utility is calculated by relating the scores 
of the five domains (1 = no problems, 2 = some problems and 3 = severe problems) to a health state valuation system established with 
the general population. The differences in the valuations may be partly due to methodological differences and partly to specific national 
characteristics where Italian scores are markedly higher throughout.
EDSS: Expanded Disability Status Scale.
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Table 3. Resource utilisation, health care and community services.
Users Percentage 
of sample
Mean number 
of times (SD)
Mean number 
of days (SD)
Hospitalisation (3 months)
 Inpatient admission 46 4.6  
  Neurology ward 35 3.5 5.7 (16.9) 10.9 (16.7)
  Other wards 17 1.7 4.3 (8.6) 23.7 (25.7)
 Day admission 187 18.5  
  Neurology ward 166 16.4 – 3.2 (3.6)
  Other wards 27 2.7 – 3.4 (4.6)
 Rehabilitation centre 89 8.8  
  Inpatient admission 20 2.0 – 5.5 (15.1)
  Day admission 81 8.0 13.0 (15.0)
 Nursing home 11 1.1 33.7 (32.2)
Consultations (3 months)
 Any type of consultation 820 81.2  
 Neurologist 713 70.6 2.0 (4.1) –
 Internist 12 1.2 1.3 (0.6) –
 Urologist 66 6.5 1.6 (1.3) –
 Ophthalmologist 117 11.6 1.5 (0.9) –
 Psychiatrist 53 5.2 3.1 (3.8) –
 General practitioner 189 18.7 3.6 (6.9) –
 MS nurse 72 7.1 4.6 (11.4) –
 Continence advisor 22 2.2 5.7 (5.5) –
 Physical therapist 209 20.7 19.4 (15.3) –
 Occupational therapist 22 2.2 10.4 (8.4) –
 Speech therapist 22 2.2 11.5 (11.3) –
 Acupuncturist 8 0.8 5.6 (4.8) –
 Chiropractor 9 0.9 3.9 (3.1) –
 Counsellor 68 6.7 6.9 (7.1) –
 Homeopath 12 1.2 2.9 (2.0) –
 Massage therapist 20 2.0 10.9 (13.0) –
 Telephone consultation MS nurse 74 7.3 2.4 (2.1) –
 Telephone consultation neurologist 208 20.6 3.1 (3.5) –
Tests (3 months)
 Any kind of test 633 62.7  
 MRI (brain) 360 35.6 – –
 MRI (spine) 258 25.5 – –
 Ultrasound 72 7.1 – –
 Blood tests 561 55.5 –
Medication (1 month)
 Any kind of medication 922 91.3 – –
 DMT 694 68.7 – –
 Corticosteroids 88 8.7 – –
 Symptomatic prescription drugs 535 53 – –
  Walking, spasticity, pain 222 22.0 – –
  Urological 70 6.9 – –
  Fatigue 46 4.6 – –
  Depression 113 11.2 – –
 OTC drugs 650 64.4 – –
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Users Percentage 
of sample
Mean number 
of times (SD)
Mean number 
of days (SD)
Equipments, aids, modifications (12 months)
 Any kind of equipment 22 22.7  
 Lifts, elevators, ramps, rails 37 3.7 –
 Walking aids 112 11.1 –
 Wheelchair use (manual, electric) 85 8.4 –
 House and car modifications 107 10.6 –
Community services (1 month)
 Any kind of service 174 17.2  
 Home help (days) 106 10.5 – 14.2 (10.7)
 Transportation (trips) 81 8.0 – 6.6 (6.4)
 Personal assistance (days) 19 1.9 – 10.0 (11.3)
SD: standard deviation; MS: multiple sclerosis; MRI: magnetic resonance imaging; DMT: disease-modifying treatment; OTC: over-
the-counter drug.
Table 3. (Continued)
Figure 5. Use of informal care (days per month and hours per day, per user).
EDSS: Expanded Disability Status Scale.
Intensity of use of informal care (number of days and hours per day during the past month). Overall, 44% of the patients rely on family 
support. Use increases with advancing disability, with 24% of the patients in the mild, 61% in the moderate and 78% in the severe group 
relying on family.
Disease symptoms and utility were very similar to 
those found in the other countries of the survey, attest-
ing to the fact that the severity of the disease affects 
patients in the same way regardless of jurisdiction or 
heath care systems. In particular, in patients with 
advanced disability, all domains of HRQoL were 
compromised. The negative effect of MS is thus evi-
dent in different aspects of daily life and functioning, 
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with different implications also for health policy. For 
instance, there is a need for more persistent monitor-
ing to ensure that patients can benefit from appropri-
ate social care.
Resource utilisation reflects the organisation of the 
Italian health care system, but certain tendencies are 
similar to the other countries. For example, compared 
to the study in 2005, inpatient care has declined very 
much, while the use of DMTs and of MRIs has 
increased.5 However, the decrease in inpatient care 
may also partly be explained by fewer patients report-
ing a relapse than in 2005 as relapses often lead to 
hospitalisation. Similarly, the high percentage of 
DMT users in this study may partly be explained by 
the overrepresentation of patients with early or mild 
disease. The proportional use of specific DMTs was 
comparable to what is recorded in the Italian 
Barometer of MS in 2016 (www.aism.it). The consid-
erable use of newer DMTs (almost 40% of users) may 
explain the increase in day admissions seen in this 
study, as a result of drug administration for some of 
the newer treatments. It also contributes to the overall 
increase in DMT costs, highlighted also in other stud-
ies,8,27,28 and representing about 75% of total costs for 
patients with mild disability.
Some of the other differences with the 2005 study 
also appear to be driven mostly by the fact that 
patients in the earlier sample had more severe disa-
bility: in this study, fewer patients had physiother-
apy sessions, fewer had invalidity pensions and 
fewer used informal care. However, the proportion 
of patients requiring informal care increased from 
24% at EDSS of 0–3 to 60% at EDSS of 4–6.5 and 
78% at EDSS of 7–9. For this latter group, informal 
care represented over 20% of the total cost. Our 
findings appear to reflect the strong family ties in the 
Italian society and a specific attitude towards the use 
of family help.
An important finding of this study is the over-
whelming presence of fatigue in almost all patients 
and the importance of cognitive difficulties, regard-
less of disease severity, seen also in other stud-
ies.29,30 Similarly, problems with anxiety and 
depression are present at the same level (in around 
50% of the patients) throughout the disease. While 
our data do not allow investigating causal effects, it 
is of note that in all 16 countries in the study, a 
substantial number of patients are not able to work 
due to MS already very early in the disease and 
with basically no physical disability. Thus, the 
results of our study corroborate previous findings 
in German MS patients that ‘invisible’ symptoms 
such as fatigue, cognitive difficulties and mood dis-
orders may have an enormous impact on work 
ability.31
Figure 6. Total mean annual cost per patient by disease severity and by level of EDSS (N = 1010).
EDSS: Expanded Disability Status Scale; DMT: disease-modifying treatment.
Total costs increase with disease severity, but the type of resources changes. DMTs completely dominate costs in very early disease, 
but hospitalisation, informal care and production losses dominate costs from EDSS 5 and higher. Community care and services are only 
provided to severely disabled patients (EDSS 9).
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Table 4. Total mean annual cost per patient by disease severity (mild, moderate and severe), N = 1010 (EUR 2015).
Mild Moderate Severe
 EDSS = 0–3 EDSS = 4–6.5 EDSS = 7–9
 Mean (SD) Mean (SD) Mean (SD)
Total costs 22,900 (17,500) 40,100 (44,500) 53,300 (48,300)
Health-care costs 20,132 (15,256) 23,611 (38,354) 15,670 (39,762)
 Inpatient care 769 (8435) 5133 (36,356) 7091 (36,839)
 Day admission 805 (2954) 1924 (4967) 1211 (3759)
 Consultations 315 (567) 959 (1645) 1137 (1615)
 Tests 671 (771) 749 (819) 268 (553)
 Medication 394 (558) 704 (830) 999 (1106)
 DMTs 17,177 (11,340) 14,141 (13,959) 4964 (9872)
Services and informal care costs 1044 (3080) 6994 (10,305) 19,575 (19,780)
 Community services 73 (500) 903 (3279) 5648 (16,433)
 Investments 79 (714) 985 (3292) 1600 (3332)
 Informal care 892 (2861) 5105 (8191) 12,328 (12,143)
Total direct cost 21,175 (15,798) 30,605 (40,492) 35,245 (44,543)
Short term absence 724 (2304) 556 (2352) 100 (684)
Long term absence, invalidity, 
early retirement
994 (5578) 8986 (15,469) 17,945 (19,080)
Total indirect cost 1717 (5915) 9542 (15,324) 18,045 (18,997)
EDSS: Expanded Disability Status Scale; SD: standard deviation; DMT: disease-modifying treatment.
Figure 7. Relapse costs (3 months).
DMTs: disease-modifying treatments; EDSS: Expanded Disability Status Scale.
Mean total 3-month costs for patients with an EDSS between 0 and 6 with and without a relapse (111 and 523 patients, respectively). 
The cost of a relapse is calculated as the difference between the two groups, excluding DMTs, invalidity and early retirement (€2600). 
The difference arises essentially from hospital care, informal care and sickness absences.
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In conclusion, these data not only contribute to the 
existing literature on cost of MS but also characterise 
various aspects of the burden of MS on patients and 
society and capture patterns of resource utilisation 
that could inform future policy recommendations. In 
addition, these data provide input into cost-effective-
ness analyses for reimbursement decisions.
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